Allied in the Fight against Viral Infectious Diseases

In order to accelerate our research and development efforts and advance product candidates, we collaborate with the following strategic partners:

National Institute of Allergy and Infectious Diseases (NIAID), USA: A key component of the US National Institutes of Health (NIH), the NIAID is conducting antiviral assessments of TSG’s drug candidates against various virus strains.
US Army Medical Research Institute of Infectious Diseases (USAMRIID), USA: A leading authority in the field of infectious disease research and biodefense, USAMRIID is evaluating the inhibitory activity of TSG’s drug candidates against various virus strains.
WHO Collaborating Center for Research on Rabies Pathogenesis and Prevention and Red Cross Society, Thailand: Determining the effectiveness of TSG's drug candidates to treat Rabies virus infection in animal models.
Vanderbilt University, USA: Evaluating the inhibitory activity of TSG's drug candidates.
Korea University, Korea: Evaluating the inhibitory activity of TSG's drug candidates.
Korea Research Institute of Chemical Technology, Korea: Evaluating the inhibitory activity of TSG's drug candidates.
Public Health England - National Infection Service, UK: Evaluated the antiviral activity of TSG's drug candidate.
Ghent University, Belgium: Evaluated the effectiveness of TSG's drug candidates to cross the blood-brain barrier for treatment of viral infections in the brain.